View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
 PRESS RELEASE

Gilat Awarded $5 Million Order from the US Department of Defense

Gilat Awarded $5 Million Order from the US Department of Defense Gilat to provide DKET 3421 terminals for easy-to-deploy transportable satcom network hubs PETAH TIKVA, Israel, March 28, 2024 (GLOBE NEWSWIRE) -- Gilat Satellite Networks Ltd. (Nasdaq: GILT, TASE: GILT), a worldwide leader in satellite networking technology, solutions, and services, announced today that the US Department of Defense awarded another $5 million order to one of the company’s US-based subsidiaries, DataPath. This additional order is for DKET 3421 terminals, transportable satcom hubs that deliver the operational...

 PRESS RELEASE

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Fi...

Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing Announces strategic portfolio reprioritization focused on rapid advancement of clinical-stage programs for XTX301, a tumor-activated, IL-12, and XTX101, a tumor-activated, Fc-enhanced anti-CTLA-4, and leveraging the company’s promising research platform for tumor-activated bispecific and cell engager molecules Reports additional Phase 2 data for XTX202, a tumor-activated, beta-gamma biased IL-2, supporting potential as combination therapy; plans to discontinue monotherapy development and evaluate collaboration op...

 PRESS RELEASE

Kraig Biocraft Laboratories Shares Industry Update on Recombinant Spid...

Kraig Biocraft Laboratories Shares Industry Update on Recombinant Spider Silk from Waste Plastics ANN ARBOR, Mich., March 28, 2024 (GLOBE NEWSWIRE) -- Kraig Biocraft Laboratories, Inc. (OTCQB: KBLB) ("Kraig Labs" or "the Company"), comments on an exciting advancement in spider silk engineering from the Rensselaer Polytechnic Institute ("RPI"). Researchers at RPI published a paper in Microbial Cell Factories outlining a new and novel method of creating spider silk protein from waste plastics. This project used a new strain of Pseudomonas bacteria capable of converting depolymerized p...

 PRESS RELEASE

Shimmick Corporation Announces Fourth Quarter and Fiscal Year 2023 Res...

Shimmick Corporation Announces Fourth Quarter and Fiscal Year 2023 Results Shimmick realized significant progress with 24% growth in Shimmick Projects, with gross margin of 7% IRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Shimmick Corp. (NASDAQ: SHIM), a leading water infrastructure company, today announced financial results for the fiscal year ended December 29, 2023. Fiscal Year 2023 Highlights Completed Initial Public Offering in November 2023Reported revenue of $633 million, which includes $434 million of Shimmick Projects revenue, an increase of 24% for fiscal y...

 PRESS RELEASE

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial...

atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights Strategic investment in Beckley Psytech to accelerate the development of psychedelic-based therapies that fit within the two hour in-clinic treatment paradigm established by Spravato®Initial BPL-003 (intranasal 5-MeO-DMT) Phase 2a open-label results demonstrated a rapid and durable antidepressant effect through three months in TRD patients; top-line results from a controlled Phase 2b TRD study anticipated in 2H 2024Dosing commenced in VLS-01 (oral transmucosal DMT) P...

 PRESS RELEASE

Total voting rights

Total voting rights 28 MARCH 2024 NORTHERN VENTURE TRUST PLC TOTAL VOTING RIGHTS In conformity with the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules (the “DTRs”), Northern Venture Trust PLC (“the Company”) notifies the market that the capital of the Company as at 28 March 2024 consists of 190,460,878 ordinary shares with a nominal value of 25p each. All the ordinary shares have voting rights. The Company does not hold any ordinary shares in treasury. The total number of voting rights in the Company is therefore 190,460,878 (“the Figure”). The Figure may be use...

 PRESS RELEASE

Total voting rights

Total voting rights 28 MARCH 2024 NORTHERN 2 VCT PLC TOTAL VOTING RIGHTS  In conformity with the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules (the “DTRs”), Northern 2 VCT PLC (the “Company”) notifies the market that the capital of the Company as at 28 March 2024 consists of 208,675,544 ordinary shares with a nominal value of 5p each. All the ordinary shares have voting rights. The Company does not hold any ordinary shares in treasury. The total number of voting rights in the Company is therefore 208,675,544 (“the Figure”). The Figure may be used by a sharehol...

 PRESS RELEASE

Manhattan Bridge Capital, Inc. Announces Payment of Quarterly Dividend

Manhattan Bridge Capital, Inc. Announces Payment of Quarterly Dividend GREAT NECK, N.Y., March 28, 2024 (GLOBE NEWSWIRE) -- Manhattan Bridge Capital, Inc. (NASDAQ: ) announced today that, in accordance with the board approved dividend declared on February 7, 2024, a cash dividend of $0.115 per share will be paid to all shareholders of record on April 10, 2024. The dividend will be paid on April 15, 2024. Contact: Assaf Ran, CEO (516) 444-3400

 PRESS RELEASE

Stran & Company Reports 28.7% Increase in Sales and Achieves Profitabi...

Stran & Company Reports 28.7% Increase in Sales and Achieves Profitability for the 2023 Fiscal Year Benefitting from Increased Operating Efficiency and Economies of Scale, Evidenced by 156% Year-Over-Year Increase in Operating Income for the Fourth Quarter of 2023 Reports Net Earnings of $883,000 for the Fourth Quarter of 2023 Conference call to be held today at 10:00 AM ET QUINCY, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Stran & Company, Inc. ("Stran" or the "Company") (NASDAQ: SWAG) (NASDAQ: SWAGW), a leading outsourced marketing solutions provider that leverages its promotional pro...

 PRESS RELEASE

Milestone Pharmaceuticals Announces Resubmission of New Drug Applicati...

Milestone Pharmaceuticals Announces Resubmission of New Drug Application for Etripamil for Treatment in Paroxysmal Supraventricular Tachycardia MONTREAL and CHARLOTTE, N.C., March 28, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the resubmission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for etripamil, the Company’s lead investigational product for the management of paroxysmal supraventricular...

 PRESS RELEASE

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financia...

Iterum Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results --Resubmission of NDA On Track for Early Q2 24— --Cash Runway into 2025, including through Potential FDA Approval in Early Q4 24-- --Company to host conference call today at 8:30amET-- DUBLIN, Ireland and CHICAGO, March 28, 2024 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today reported fina...

 PRESS RELEASE

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Fin...

Apollomics Highlights Clinical Progress and Reports Full Year 2023 Financial Results Continued clinical and regulatory progress for the vebreltinib (APL-101) registration-enabling programCompleted patient enrollment for the uproleselan (APL-106) Phase 3 bridging study in China – topline data expected in the first half of 2025$37.8 million in cash, cash equivalents and money market funds as of December 31, 2023, with a cash runway through first quarter 2025Management to host conference call today, Thursday, March 28, 2024 at 8:30 a.m. ET FOSTER CITY, Calif., March 28, 2024 (GLOBE NEWS...

 PRESS RELEASE

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activa...

Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program -- Gilead Granted Exclusive License to Xilio’s Tumor-Activated IL-12 Program, Including XTX301, a Clinical-Stage IL-12 Molecule with Potential to Treat a Broad Range of Cancers -- FOSTER CITY, Calif. and WALTHAM, Mass., March 28, 2024 (GLOBE NEWSWIRE) -- Gilead Sciences, Inc. (Nasdaq: GILD) and Xilio Therapeutics, Inc. (Nasdaq: XLO) today announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301. Xilio Therapeutics is a clinical-stage ...

 PRESS RELEASE

Data Storage Corporation Reports Record Revenue of $25 Million and Ach...

Data Storage Corporation Reports Record Revenue of $25 Million and Achieves Profitability for the 2023 Fiscal Year MELVILLE, N.Y., March 28, 2024 (GLOBE NEWSWIRE) -- Data Storage Corporation (Nasdaq: DTST) (“DSC” and the “Company”), a provider of diverse business continuity solutions for disaster-recovery, cloud infrastructure, cyber-security, and IT services, today provided a business update and reported financial results for the year ended December 31, 2023. Chuck Piluso, CEO of Data Storage Corporation, stated, “We are proud to report record revenue of $25.0 million for the 2023 f...

 PRESS RELEASE

Tilray Brands, Inc. to Announce Third Quarter 2024 Financial Results o...

Tilray Brands, Inc. to Announce Third Quarter 2024 Financial Results on April 9, 2024 NEW YORK and LEAMINGTON, Ontario, March 28, 2024 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. (“Tilray” or the “Company”) (Nasdaq: TLRY; TSX: TLRY), a leading global cannabis-lifestyle and consumer packaged goods company, today announced that the Company will release financial results for its third quarter ended February 29, 2024, on April 9, 2024. Live Audio Webcast Tilray will host a live audio webcast to discuss these results at 8:30 am Eastern Time, which can be accessed on the Investors section of Tilr...

 PRESS RELEASE

Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR ...

Purple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024 NT219 found to suppress cancer stem cells that promote drug resistance to KRASG12C and KRASG12D inhibitors and solid tumor recurrence Potential biomarkers for treatment with NT219 detected in responding patients in Phase 1 REHOVOT, Israel, March 28, 2024 (GLOBE NEWSWIRE) --   ("Purple Biotech" or "the Company") (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today annou...

 PRESS RELEASE

Mayfair Gold Commences 2024 Environmental Field Program at Fenn-Gib Go...

Mayfair Gold Commences 2024 Environmental Field Program at Fenn-Gib Gold Project MATHESON, Ontario, March 28, 2024 (GLOBE NEWSWIRE) -- Mayfair Gold Corp. (“Mayfair” or the “Company”) (TSX-V: MFG; OTCQB: MFGCF) today announced the start the 2024 environmental field program in support of a potential environmental assessment for the 100% controlled Fenn-Gib project in the Timmins region of Ontario. The program is being managed by a multi-disciplinary group led by Environmental Applications Group Inc. of Sudbury, Ontario. Mayfair’s president and CEO, Patrick Evans, commented: “This represent...

 PRESS RELEASE

Aya Gold & Silver: Record 2023 Production, Revenue and Operating Cash ...

Aya Gold & Silver: Record 2023 Production, Revenue and Operating Cash Flow Announces 2024 Guidance MONTREAL, March 28, 2024 (GLOBE NEWSWIRE) -- Aya Gold & Silver Inc. (TSX: AYA, OTCQX: AYASF) (“Aya” or the “Corporation”) is pleased to announce financial and operational results for the fourth quarter and year ended December 31, 2023. All amounts are in US dollars, unless otherwise stated. Annual Highlights Exceeded 2023 production guidance with silver production of 1.97 million ounces (“oz”), a 5% increase from 2022.Ore processed of 281,634 tonnes (“t”) in 2023, a 10% increase from 254...

 PRESS RELEASE

Aya Or & Argent annonce une production, des revenus et des flux de tré...

Aya Or & Argent annonce une production, des revenus et des flux de trésorerie d’exploitation records en 2023 et présente ses prévisions pour 2024 MONTRÉAL, 28 mars 2024 (GLOBE NEWSWIRE) -- Aya Or & Argent Inc. (TSX : AYA, OTCQX : AYASF) (« Aya » ou la « Société ») a le plaisir d’annoncer ses résultats financiers et opérationnels pour le quatrième trimestre et l’exercice terminés le 31 décembre 2023. Tous les montants sont en dollars américains à moins d’indication contraire. Faits saillants annuels Dépassement de la production prévue pour 2023 avec une production de 1,97 million d’onces...

 PRESS RELEASE

ARKO Corp. Negotiates Enhanced Value for Stockholders in Final Payment...

ARKO Corp. Negotiates Enhanced Value for Stockholders in Final Payment for TEG Acquisition RICHMOND, Va., March 28, 2024 (GLOBE NEWSWIRE) -- ARKO Corp. (Nasdaq: ARKO) (“ARKO” or the “Company”), a Fortune 500 company and one of the largest convenience store operators in the United States, announced today that it has negotiated improved deferred payment terms and value related to the Company’s previously reported acquisition of the assets of Transit Energy Group and its affiliates (“TEG”). As previously disclosed, on March 1, 2023, the Company closed on the acquisition from TEG of 135 co...

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch